The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| RMTI | -67.05% | -89.2% | -35.93% | -98% |
| S&P | +14.5% | +93.32% | +14.09% | +591% |
Rockwell Medical, Inc. is a biopharmaceutical company, which engages in the development of treatment for anemia, kidney disease, iron deficiency, and hemodialysis. Its products include Triferic, CitraPure, RenalPure and SteriLyte. The company was founded by Robert L. Chioini in January 1995 and is headquartered in Wixom, MI.
The price of Rockwell Medical's latest stock offering wasn't right for investors.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $16.07M | -37.8% |
| Gross Profit | $2.50M | -45.0% |
| Gross Margin | 15.57% | -2.0% |
| Market Cap | $28.98M | -45.7% |
| Market Cap / Employee | $0.12M | 0.0% |
| Employees | 244 | 3.0% |
| Net Income | -$1.49M | -623.5% |
| EBITDA | -$0.79M | -173.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $12.48M | 5.2% |
| Accounts Receivable | $8.08M | -25.4% |
| Inventory | 4.2 | -29.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $11.27M | -3.5% |
| Short Term Debt | $2.74M | 1.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -4.41% | 6.2% |
| Return On Invested Capital | -60.69% | 30.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $1.68M | 45.3% |
| Operating Free Cash Flow | $1.84M | 27.9% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 5.24 | 2.26 | 1.18 | 0.92 | -63.43% |
| Price to Sales | 1.30 | 0.66 | 0.39 | 0.33 | -44.63% |
| Price to Tangible Book Value | 10.19 | 3.69 | 1.79 | 1.41 | -75.25% |
| Price to Free Cash Flow TTM | 48.85 | 21.02 | 17.84 | 10.84 | - |
| Enterprise Value to EBITDA | 50.27 | 2565.41 | -41.51 | -31.40 | -156.73% |
| Free Cash Flow Yield | 2.0% | 4.8% | 5.6% | 9.2% | - |
| Return on Equity | -6.0% | -2.9% | -2.1% | -8.6% | -70.43% |
| Total Debt | $14.18M | $13.54M | $12.87M | $14.01M | -2.57% |
RMTI earnings call for the period ending June 30, 2019.
RMTI earnings call for the period ending March 31, 2019.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
